|
ИСТИНА |
Войти в систему Регистрация |
ИСТИНА ИНХС РАН |
||
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinomaстатья
Статья опубликована в высокорейтинговом журнале
Статья опубликована в журнале из списка Web of Science и/или Scopus- Авторы: Finn Richard S., Qin Shukui, Ikeda Masafumi, Galle Peter R., Ducreux Michel, Kim Tae-You, Kudo Masatoshi, Breder Valeriy, Merle Philippe, Kaseb Ahmed O., Li Daneng, Verret Wendy, Xu Derek-Zhen, Hernandez Sairy, Liu Juan, Huang Chen, Mulla Sohail, Wang Yulei, Lim Ho Yeong, Zhu Andrew X., Cheng Ann-Lii
- Журнал: New England Journal of Medicine
- Том: 382
- Номер: 20
- Год издания: 2020
- Издательство: Massachusetts Medical Society
- Местоположение издательства: United States
- Первая страница: 1894
- Последняя страница: 1905
- DOI: 10.1056/nejmoa1915745
- Аннотация: The combination of atezolizumab and bevacizumab showed encouraging antitumor activity and safety in a phase 1b trial involving patients with unresectable hepatocellular carcinoma. METHODS In a global, open-label, phase 3 trial, patients with unresectable hepatocellular carcinoma who had not previously received systemic treatment were randomly assigned in a 2:1 ratio to receive either atezolizumab plus bevacizumab or sorafenib until unacceptable toxic effects occurred or there was a loss of clinical benefit. The coprimary end points were overall survival and progression-free survival in the intention-to-treat population, as assessed at an independent review facility according to Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1). RESULTS The intention-to-treat population included 336 patients in the atezolizumab–bevacizumab group and 165 patients in the sorafenib group. At the time of the primary analysis (August 29, 2019), the hazard ratio for death with atezolizumab–bevacizumab as compared with sorafenib was 0.58 (95% confidence interval [CI], 0.42 to 0.79; P<0.001). Overall survival at 12 months was 67.2% (95% CI, 61.3 to 73.1) with atezolizumab–bevacizumab and 54.6% (95% CI, 45.2 to 64.0) with sorafenib. Median progression-free survival was 6.8 months (95% CI, 5.7 to 8.3) and 4.3 months (95% CI, 4.0 to 5.6) in the respective groups (hazard ratio for disease progression or death, 0.59; 95% CI, 0.47 to 0.76; P<0.001). Grade 3 or 4 adverse events occurred in 56.5% of 329 patients who received at least one dose of atezolizumab–bevacizumab and in 55.1% of 156 patients who received at least one dose of sorafenib. Grade 3 or 4 hypertension occurred in 15.2% of patients in the atezolizumab–bevacizumab group; however, other high-grade toxic effects were infrequent. CONCLUSIONS In patients with unresectable hepatocellular carcinoma, atezolizumab combined with bevacizumab resulted in better overall and progression-free survival outcomes than sorafenib. (Funded by F. Hoffmann–La Roche/Genentech; ClinicalTrials.gov number, NCT03434379. opens in new tab.)
- Добавил в систему: Бредер Валерий Владимирович